Press Release - SUTUREGARD® Presenting at the American Society for Mohs Surgery

SUTUREGARD® Medical, Inc. Blog

 
21Jan

Press Release - SUTUREGARD® Presenting at the American Society for Mohs Surgery

Press Release | | Return|

SUTUREGARD® Medical will be presenting at the American Society for Mohs Surgery (ASMS) Closure Course in Phoenix, AZ the weekend of January 25th-26th, 2020. "This is our second year at the ASMS Closure Course. We are very excited to be launching our second product, the HEMIGARD™ Adhesive Retention Suture Device, at this course", says SUTUREGARD® Medical's COO, Jen Akeroyd, PhD, RN. The HEMIGARD™, for short, allows surgeons to close fragile skin wounds with suture without tearing the skin.

The HEMIGARD™ allows surgeons to put more than twice the force on suture without damaging the skin compared to other commercially available adhesive-tape devices. In appropriate cases, surgeons will be able to avoid skin grafts and second intent healing when using the HEMIGARD™. The product has been trialed by surgeons and is FDA registered. Peer-reviewed publications are in-press, including: Roybal, L., Blattner, C., Young, J. & Lear, W. (In press). A novel adhesive suture retention device for the closure of fragile skin under tension. JAAD Case Reports.

"ASMS courses are intimate, allowing us to build strong relationships with attendees. We launched the SUTUREGARD® ISR device at a ASMS conference in November 2018 and returned to that conference November 2019. We are excited to see familiar faces and develop new relationships at the Closure Course", says Jen.

Based in Portland, Oregon, SUTUREGARD® Medical, Inc is a private company offering novel medical devices for surgeons to repair challenging surgical defects more simply. SUTUREGARD® medical devices are intended to provide minimal wound trauma and reduce the healing period after surgery, providing better results for patients overall.

Related

What is Squamous Cell Carcinoma (SCC)?

Squamous cell carcinoma (SCC) is the second most common skin cancer. While basal cell carcinoma (BCC...

Read More >

The Next Step In Incision Management: Reducing Surgical Wound Dehiscence

Surgical wound dehiscence is one of the most dreaded & costly of surgical complications. It is distu...

Read More >

No Undermining? Are You Kidding Me?

By: Dan Ladizinsky, MD, CEO, SUTUREGARD Medical, Retired Board Certification in General Surgery, Pla...

Read More >

What is Basal Cell Carcinoma (BCC)?

A basal cell carcinoma (BCC) is one of the most common skin cancers. Every year, there are over 4 mi...

Read More >

Eliminate suture removals – with HEMIGARD!

"When I want to eliminate patient post-op visits for suture removal, I have been using the HEMI...

Read More >

Press Release - SUTUREGARD® Medical, Inc is Presenting at Arab Health

SUTUREGARD® Medical, Inc is excited to announce that CEO Dan Ladizinsky, MD, will be presenting SUTU...

Read More >

Relax & Close, More Wounds, More Simply.

Making wound closure easier for surgeons and better for patients.

Order Now